Compare CMCM & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCM | BNR |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | China | China |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.5M | 216.9M |
| IPO Year | 2014 | 2020 |
| Metric | CMCM | BNR |
|---|---|---|
| Price | $6.30 | $33.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.4K | ★ 32.3K |
| Earning Date | 11-26-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $151,517,306.00 | $75,749,382.00 |
| Revenue This Year | $14.27 | $136.32 |
| Revenue Next Year | $39.26 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 46.34 | 5.56 |
| 52 Week Low | $3.28 | $2.18 |
| 52 Week High | $9.44 | $41.72 |
| Indicator | CMCM | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 43.48 | 55.86 |
| Support Level | $5.92 | $32.75 |
| Resistance Level | $6.88 | $41.09 |
| Average True Range (ATR) | 0.29 | 4.27 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 32.20 | 52.78 |
Cheetah Mobile Inc along with its subsidiaries provides comprehensive products and services on PCs and mobile devices. It generates revenue from utility-related business, including advertising services and premium membership services. It also provides multi-cloud management platform and overseas advertising agency service. The company operates in two segments: Internet business, and AI and others. The firm's majority of the revenue is derived from the internet business segment that provides mobile advertising services to advertising customers, as well as selling advertisements and referring user traffic on its mobile and PC platforms. Geographically, it derives the majority of its revenue from the PRC and the rest from Hong Kong, Japan, and the rest of the world.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.